CTLA4 and neoplasm: The results revealed that neither the immunotherapy cocktail nor Doxil monotherapy affected tumor growth, whereas a combination of the three components (PD-1 and CTLA-4 antibodies, Doxil nanomedicine, and tranilast) resulted in a significant reduction exceeding 50% compared to the untreated group.